<DOC>
	<DOCNO>NCT00088985</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy , vinorelbine , work different way stop tumor cell divide stop grow die . Combining vaccine therapy monoclonal antibody therapy chemotherapy may kill tumor cell . PURPOSE : This phase II trial study well give vaccine therapy together trastuzumab vinorelbine work treat woman locally recurrent metastatic breast cancer .</brief_summary>
	<brief_title>Vaccine Therapy , Trastuzumab , Vinorelbine Treating Women With Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine efficacy multiepitope autologous dendritic cell vaccine , trastuzumab ( Herceptin^® ) , vinorelbine measure change large dimension metastatic lesion , woman locally recurrent metastatic breast cancer overexpress HER2/neu . Secondary - Determine ability regimen induce functional antigen-specific T cell patient measure ex-vivo antigen-specific T-cell activity peptide-pulsed dendritic cell tumor target tetramer stain intracellular cytokine assay . OUTLINE : - Autologous dendritic cell mobilization harvest : All patient undergo autologous dendritic cell mobilization filgrastim ( G-CSF ) and/or sargramostim ( GM-CSF ) subcutaneously daily 4 day follow apheresis . Mobilized peripheral blood process production dendritic cell CD34-positive cell selection . The dendritic cell expand pulsed E75 E90 peptide . - Treatment : Patients receive vinorelbine IV 6-10 minute trastuzumab ( Herceptin ^® ) IV 90 minute day 1 . Patients also receive autologous dendritic cell pulse E75 E90 peptides subcutaneously 2-5 minute day 1* . Treatment repeat every 14 day 6 course absence disease progression unacceptable toxicity . NOTE : *If treatment give locally , vaccine therapy give UNC-Chapel Hill follow day . Patients follow every 3 month . PROJECTED ACCRUAL : A total 17-37 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm breast cancer Locally recurrent metastatic disease HLAA0201 positive DNA genotyping HER2/neu expression least 1+ immunohistochemistry tumor sample CNS metastases allow provided therapy 3 month stable Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Female Menopausal status Not specify Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count &gt; 1,500/mm^3 Platelet count &gt; 100,000/mm^3 Hematocrit &gt; 33 % Hepatic Transaminases ≤ 3 time upper limit normal Bilirubin ≤ 2 time normal Hepatitis B surface antigen negative Renal Creatinine &lt; 2.0 mg/dL Cardiovascular Ejection fraction &gt; 45 % MUGA OR Left ventricular function normal echocardiogram No serious cardiac condition would preclude study participation compliance Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No serious medical psychiatric condition would preclude study participation compliance PRIOR CONCURRENT THERAPY : Biologic therapy Prior biologic therapy allow Chemotherapy More 30 day since prior cytotoxic chemotherapy No concurrent chemotherapy Endocrine therapy More 30 day since prior hormonal therapy No concurrent hormonal therapy No concurrent systemic steroid Radiotherapy Not specify Surgery Not specify Other Concurrent bisphosphonates bone metastasis allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>